en · de · es · fr · pt
faq-desk.peptides6155.com › Topic › Background And Mechanism — Worked Examples

Background And Mechanism — Worked Examples

By Editorial Desk · published 2025-10-20 · last reviewed 2025-11-27 · Topic

HPLC-UV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-11-27. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Analytical Detection and Laboratory Handling

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SDerived from published structure.
Molecular weight437.94 g/molCalculated value.
AppearanceWhite to off-white solidTypical for purified research samples.
SolubilityDMSO, ethanol; low in waterClass: poorly water-soluble.
Typical storage-20 °C, desiccated, protected from lightLimits degradation.

SR9009 Identity and Mechanism

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

Related pages on this site

Supporting material

In 1913 the structure of sodium chloride was determined by William Henry Bragg and his son William Lawrence Bragg. This revealed that there were six equidistant nearest neighbours for each atom, demonstrating that the constituents were not arranged in molecules or finite aggregates, but instead as a network with long-range crystalline order. Many other inorganic compounds were also found to have similar structural features. These compounds were soon described as being constituted of ions rather than neutral atoms, but proof of this hypothesis was not found until the mid-1920s, when X-ray reflection experiments (which detect the density of electrons), were performed. Principal contributors to the development of a theoretical treatment of ionic crystal structures were Max Born, Fritz Haber, Alfred Landé, Erwin Madelung, Paul Peter Ewald, and Kazimierz Fajans. Born predicted crystal energies based on the assumption of ionic constituents, which showed good correspondence to thermochemical measurements, further supporting the assumption.

=== Multiple sclerosis === Induced T regulatory cells (iTreg), stimulated by TGF-β in the presence of IL-2, suppressed the development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS) via a FOXP3 and IL-10 mediated response. This suggests a possible role for TGF-β and iTreg in the regulation and treatment of MS. Decreased levels of TGF-β have been observed in patients diagnosed with multiple sclerosis. Its role in multiple sclerosis can be explained due to TGF-β role in regulating apoptosis of Th17 cells. When TGF-β levels decrease, they are unable to induce Th17 cells' apoptosis. Th17 cells secrete TNF-α, which induces demyelination of the oligodendroglial via TNF receptor 1. The decreased TGF-β levels lead to increased Th17 cells and subsequently increased TNFα levels. As a result, demyelination of neurons occurs. TGF-β have also been observed to induce oligodendrocyte (myelin sheath producing cells) growth. Hence, the decreased TGF-β levels during MS may also prevent remyelination of neurons.

Downtown Emergency Service Center (DESC), in Seattle, Washington, operates several Housing First programmes which utilize the harm reduction model. University of Washington researchers, partnering with DESC, found that providing housing and support services for homeless alcoholics costs taxpayers less than leaving them on the street, where taxpayer money goes towards police and emergency health care. Results of the study funded by the Substance Abuse Policy Research Program (SAPRP) of the Robert Wood Johnson Foundation appeared in the Journal of the American Medical Association in April 2009. This first controlled assessment in the U.S. of the effectiveness of Housing First, specifically targeting chronically homeless alcoholics, showed that the programme saved taxpayers more than $4 million over the first year of operation. During the first six months, the study reported an average cost-savings of 53 percent (even after considering the cost of administering the housing's 95 residents)—nearly $2,500 per month per person in health and social services, compared to the per month costs of a wait-list control group of 39 homeless people. Further, despite the fact residents are not required to be abstinent or in treatment for alcohol use, stable housing also results in reduced drinking among people experiencing homelessness who recreationally use alcohol.

Sources: en.wikipedia.org

Notes from published material

After the resignations of Kissinger's aides, Nixon took away the authority to tap phones, which he had given Kissinger in May 1969, and gave it to the attorney general, John Mitchell. Unknown to Kissinger, Mitchell had been illegally tapping his phone since the fall of 1969. Adding to the tension, on 2 May 1970, U.S. aircraft bombed North Vietnam for the first time since 1968, causing Senator Fulbright to say, "Good God", when he heard the news. Senate Majority Leader Mike Mansfield said he had trouble believing that Nixon and Kissinger were so reckless. To Nixon, Kissinger accused Laird and/or Rogers of leaking the news of the bombing raid on North Vietnam and asked for the FBI to tap their phones. Without informing Nixon, on 4 May 1970, Laird announced the end of the bombing raids on North Vietnam. On the night of 8 May 1970, Nixon, who had been rattled by the protests, stayed up all night, drinking heavily and randomly phoning people he knew. Between 11:00 pm–2:00 am, Nixon made forty calls, with Kissinger receiving eight of the calls. The Cambodian "incursion" saw American and South Vietnamese troops take the areas of eastern Cambodia that American commanders called the Fish Hook and Parrot's Beak and capture an impressive haul of arms originating from China and the Soviet Union. However, the majority of Vietnamese Communist forces had withdrawn deeper into Cambodia before the invasion, with only a small number left behind to wage a fighting retreat to avoid charges of cowardice.

== Prevention == The first control method is preventive and aims to eradicate the adult flies before they can cause any damage. The second control method is treatment once the infestation is present, and concerns the infected animals (including humans). The principal control method of adult populations of myiasis-inducing flies involves insecticide applications in the environment where the target livestock is kept. Organophosphorus or organochlorine compounds may be used, usually in a spraying formulation. One alternative prevention method is the sterile insect technique (SIT) where a significant number of artificially reared sterilized (usually through irradiation) male flies are introduced. The male flies compete with wild breed males for females to copulate and thus cause females to lay batches of unfertilized eggs that cannot develop into the larval stage. One prevention method involves removing the environment most favourable to the flies, such as by removal of the tail. Another example is the crutching of sheep, which involves the removal of wool from around the tail and between the rear legs, which is a favourable environment for the larvae. Another, more permanent, practice that is used in some countries is mulesing, where the skin is removed from young animals to tighten remaining skin – leaving it less prone to fly attack. To prevent myiasis in humans, there is a need for general improvement of sanitation, personal hygiene, and extermination of the flies by insecticides.

HIV dementia Tourette syndrome Tic disorders Attention deficit hyperactivity disorder (ADHD) Psychiatric disorders (such as schizophrenia, major depressive disorder, bipolar disorder, anxiety disorders) Multiple sclerosis Huntington's disease Encephalopathies Lipid metabolism Liver fat metabolism Systemic lupus erythematosus Glutaric aciduria Vitamin B6 deficiency Eosinophilia-myalgia syndrome Long COVID

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Is SR9009 a SARM?

No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.

Are there human trials of SR9009?

Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.

How is SR9009 detected?

It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.

Network